Good morning, ladies and gentlemen. Welcome to the CareCloud Inc. First Quarter 2023 Results Conference Call. At this time, all participants will be in a listen-only mode. Later, we will conduct a question-and-answer session. I will now turn the call over to your host, Kimberly Blanche, CareCloud's General Counsel. Ms. Blanche, you may begin.

Good morning, everyone. Welcome to the CareCloud First Quarter 2023 Conference Call. On today's call are Mahmud Haq, our Founder and Executive Chairman; Hadi Chaudhry, our Chief Executive Officer, President and Director; and Bill Korn, our Chief Financial Officer. Before we begin, I would like to remind you that certain statements made during this conference call are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All statements other than statements of historical facts made during this conference call are forward-looking statements, including, without limitation, statements regarding our expectations and guidance for future financial and operational performance, expected growth, business outlook, and potential organic growth and acquisitions. Forward-looking statements may sometimes be identified with words such as will, may, expect, plan, anticipate, upcoming, believe, estimate, or similar terminology and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These statements reflect our opinions only as of the date of this presentation, and we undertake no obligation to revise these forward-looking statements in light of new information or future events. Please refer to our press release and our reports filed with the Securities and Exchange Commission, where you will find a more comprehensive discussion of our performance and factors that could cause actual results to differ materially from these forward-looking statements. For anyone who dialed into the call by telephone, you may want to download our first quarter 2023 earnings presentation. Please visit our Investor Relations site, ir.carecloud.com, click on News & Events, then click IR calendar, click First Quarter 2023 Results Conference Call, and download the earnings presentation. Finally, on today's call, we may refer to certain non-GAAP financial measures. Please refer to today's press release announcing our first quarter 2023 results for a reconciliation of these non-GAAP performance measures to our GAAP financial results. With that said, I'll now turn the call over to our CEO, Hadi Chaudhry. Hadi?

Thank you, Kim, and thanks to all of you for joining us for our first quarter 2023 earnings call. We started 2023 building on an organic growth momentum we created throughout 2022. In the first quarter, we reported revenue of $30.1 million and adjusted EBITDA of $4.2 million. We are pleased that these numbers are in line with our internal expectations and keep us on track to deliver on our full year's guidance. Today, we will provide you with an update on our organic bookings momentum, our progress towards converting bookings into revenue recognized during the first quarter, the emerging growth opportunities in the Middle East, our increased focus on marketing efforts to raise awareness of our comprehensive solutions, and early adopters of our therapy EHR solution that I mentioned last quarter. First, I will provide an update on the continued momentum of our overall bookings with a particularly meaningful contribution from our wellness offerings, which include chronic care management and remote patient monitoring. After about a year on the market, it continues to gain traction with our physician base. Our recurring revenue bookings for the first quarter of 2023 were over $8 million. 2022 was a record year for bookings, and that certainly continued in 2023. We have seen good momentum in overall bookings, including wellness bookings over the last year, and I would like to share a little detail on how it's converting to revenue. I'm going to talk first about overall bookings conversion and then break it down by tech-enabled RCM, Force, and wellness. First off, the total recurring bookings we signed in 2022. 92% of the potential revenue has gone live with us in some form or fashion. In the first quarter, on an annualized basis, we recognized 44% of the potential revenue opportunity from those clients that have gone live. That said, each of the three businesses ranks differently. So I'm going to walk through each one of them on a stand-alone basis. For our tech-enabled RCM, we have gone live with 88% of the potential revenue we booked last year in the first quarter. On an annualized run rate, we have recognized all of those potential revenues from the live clients. As a reminder, for our RCM solution, we typically anticipate a six-month time frame from signing bookings to going live with the business. Force, which is our staffing augmentation solution, we have gone live with 96% of the potential revenue, but recognized just 4% in the first quarter, again, on an annualized basis. This is in line with our expectations, and there are a couple of factors that will cause this to ramp over the course of the year. First, the large contract that we signed late last year with a well-known publicly traded healthcare technology company is currently in the preproduction phase. Under the terms of our agreement, we are sharing SOPs, background checks, trainings, and the like before we can start recognizing revenue. Subsequent to those close to the quarter, the second largest contract went live, and the customer is very pleased with the partnership so far. Together, these contracts represent a meaningful portion of the 96% of the potential revenue, but the first contributed minimal revenue in the first quarter, and the second will contribute to our second quarter results but is not reflected in the numbers we reported today. The second factor leading to the divergence between potential revenue that has gone live and revenue recognized is that customers typically start with just a few employees and ramp up to their desired levels over time. It is our experience that customers, especially larger, more sophisticated customers, will take between three and four quarters to reach their potential. Lastly, in our wellness solution, we have gone live with 93% of potential revenue and have recognized 7% of their potential revenue on an annualized basis. In this business line, go-live is defined by having conducted monitoring with or provided services to at least one patient in the practice. We expect this to ramp over the course of the year, and there is typically a 10-month cycle of signing a physician, identifying the appropriate chronically ill patients, engaging them via mail and phone to get consent, and onboarding them. Once all of these are complete, the care managers create an individual care plan and work with physicians to implement it. We continue to work closely with our physician partners so they understand the ease of working with CareCloud and the value we provide to their patients. We look forward to sharing our progress on our next few quarters' calls. Next, I will provide an update on our efforts in the Middle East. As discussed last quarter, we remain committed to pursuing the emerging growth opportunities in the Middle East. We set our sights first on the UAE, given the government's plan to mandate EHR adoption in the next few years, similar to the meaningful use initiatives in the U.S. a decade ago. We have started making progress in this area and are very close to completing the setup of an entity in the UAE to capitalize on this potential opportunity. We are continuing to pursue the certification process and plan to hold a groundbreaking at the Precision Med Expo in the UAE at the end of May. We have already begun the process of getting our solution certified in filing for required attestations. In terms of these international opportunities, we feel CareCloud is uniquely positioned for success for a couple of reasons. Our status and reputation as a publicly traded company in the U.S., our over two decades of experience in the EHR, professional services, and tech-enabled RCM businesses, the cost-effectiveness of our scaled operations, and our cultural familiarity with this part of the world. We look forward to keeping you posted as these potentially meaningful opportunities unfold. I will now turn to an update on our marketing efforts. First, we are proud to report that for the second straight year, we were recognized in the best-in-class report under the category of small practice ambulatory EHR and practice management. This year, we are focused on continuing to raise awareness of CareCloud's offerings in the market to fuel our organic growth. We have had a meaningful presence at many of the industry conferences this year, such as WIFE and HMS. These conferences do not only provide many leads for new customers, but they also create opportunities to showcase our comprehensive solutions to the market. For some additional context, at the time of the IPO, we spent just 1% of revenue on sales and marketing. As of last year, that number had grown to 7%, and this year, it is on track to reach 8%. This current marketing campaign seeks to bring attention to our innovative solutions, including our tech-enabled RCM solution, which is truly differentiated in the market as it sits on top of industry-leading, state-of-the-art software technology products to help us drive better revenue growth in this mature EHR and practice management market. Our telecom solution, which was ahead of the curve, launched a year before the pandemic and quickly became an integral part of healthcare practices. AI has been a hot topic in the news lately. But for CareCloud, it is nothing new as we have been leveraging AI from its very early stages. Our first AI-based product launched in the early years of the company was a scrubbing engine, and we have since launched several others over the last few years. Since then, we have layered in robotic process automation bots, or RPAs, to automate mainline tasks and streamline back-office processes, in addition to being leveraged by our clients. It's never been believed that open APIs of AI will be the next wave of innovation in healthcare, similar to many other sectors. So we are evaluating ways we can effectively and safely use solutions like OpenAI and ChatGPT in a compliant and secure manner for our medical providers. We see this as a further opportunity to leverage AI to improve workflow in EHR and practice management systems as an avenue to reduce costs, increase profitability, and improve patient outcomes. We are still in the R&D phase and not yet ready to make it provider-facing. Finally, an update on our therapy market opportunity I mentioned last quarter. We are making progress with two early adopters who have already gone live. We are supporting our thesis that our end-to-end solution is a welcome change to outdated solutions prevalent in the market today. Wrapping up, CareCloud's first quarter results represent a strong start to the year and leave us well-positioned to focus on our numerous opportunities for growth throughout 2023, keeping us on track to meet our full year's expectations. With that, I will turn the call over to Bill to review the financials. Bill?

Thanks, Hadi, and thank you all for joining our call today. I'd like to start by reiterating Hadi's sentiment that we are pleased to report the first quarter results were in line with what we expected, and we are on track to achieve our full-year goals. In the first quarter, we reported revenue of $30 million. While down year-over-year, the decline can be largely attributed to three factors. First, the loss of revenue from two customers due to healthy demergers. Approximately $2.6 million of the decrease in first-quarter revenue was due to these two clients who completed migrating to their acquirer's platforms in mid-2022. Second, some softness in Med SR, which is a project-based professional services business that tends to fluctuate. Med SR revenue was down $1.2 million from first quarter 2022. Our professional services business continues to be strong. And while our expectation is that second-quarter professional services revenue will be similar to the first quarter, we have a number of major projects in our pipeline for the second half of 2023. Finally, the first quarter of 2022 included approximately $1.2 million of revenue from revenue cycle management for services, which were COVID-related. This was not present during the first quarter of 2023. Despite these three factors, we still remain confident about the full-year picture. Of the first quarter revenue, approximately 87% came from our tech-enabled business solutions and professional services. We reported a GAAP net loss of $401,000, and adjusted EBITDA came in at $4.2 million. As a reminder, our first-quarter revenue is typically down 5% to 8% from Q4 due to insurance deductibles resetting at year-end. While it is typical for our revenue to be back half weighted, in 2023, it will be more so than usual because of record bookings from new clients who are ramping up over the year, and our wellness solution, which we expect will build and become a bigger contributor in the second half of 2023. As Hadi mentioned, we expect that our new CareCloud Force clients who signed with us last year and were in preproduction during the first quarter will start generating significant revenue in the second half. Between the growing adoption of Force, more new clients continuing to go live every quarter, and wellness visits that continue accelerating as more patients start taking advantage of this new capability, we are projecting rapid organic growth during the third and fourth quarters. As for profits, the majority of our costs are fixed; a typical adjusted EBITDA cadence closely mirrors the revenue seasonality, providing another level of granularity. In the first quarter, we processed a similar number of claims as in the fourth quarter of 2022, but recognized lower revenue due to deductibles. With the same fixed cost structure, as revenue goes down, GAAP net income and adjusted EBITDA decreased, as was the case this quarter. Turning to the balance sheet, we ended the quarter with $8 million in cash. I'd like to reassure everyone that our credit relationship with Silicon Valley Bank, which is now a division of First Citizens, is sound, and they are honoring our agreement to the fullest. We ended the quarter with $10 million drawn on our $25 million line of credit, and SVB has assured us that the terms of our credit agreement are unchanged. I'll close my comments by reiterating our 2023 guidance. We expect revenue of $142 million to $146 million and adjusted EBITDA of $24 million to $27 million. As a reminder, we believe that 42% to 44% of total revenue will come in the first half of 2023 and 56% to 58% will flow through the back half of the year. As we benefit from additional revenue with the same overhead structure, we expect the adjusted EBITDA distribution will more likely look like 30% in the first half and 70% in the back half of the year as our newer offerings ramp up over the course of 2023. In terms of Med SR's quarterly cadence over the course of the year, we are seeing great traction with projects, which will result in a strong second half of 2023. So we're all going to need to be patient in the second quarter. First quarter results put us on good footing for the year ahead. We're happy with our progress on the organic growth front and look forward to updating you later in the year. With that, I'll turn the call over to Mahmud for his closing remarks.

Thank you, Bill. We are pleased with a strong start of 2023, and we are proud of the work that the CareCloud team has done to set us on the right path for a successful year. As always, I would like to thank our customers, shareholders, and all of our employees for their continued support of the CareCloud mission. Let's open the call to questions.

Thank you, everyone. We will now start the question-and-answer session. Your first question will come from Jeffrey Cohen at Ladenburg Thalmann.

I wanted to ask you, Hadi, about the AI features and the various functionalities at CareCloud, both past and present. Can you specifically discuss the ChatGPT aspect, including the verbal inputs and also touch on data mining and onboarding?

Sure, Jeff. No, that's a great question, and that's probably the most relevant hot topic in the industry today, not only from the healthcare perspective, but from an overall industry perspective. As I mentioned, we are in the process of currently exploring. Our R&D team is working on all of these, the possible ways to leverage AI with the help of OpenAI or APIs that have become available now. But I can share with you as an example that probably should help you understand the kind of things that we are trying to work on. We are in the process of, to begin within the first phase, utilizing the ChatGPTs, the most recent version, which is probably version 4.0. We can try to introduce concepts such as the copilot concept or a medical assistant concept. We already have, as part of our talk, the medical assistant or our Alison engine. So we're just trying to make that further smart. What can happen is, anonymously not sharing any PHI, we're going to take the medical history, social history, the current medication, all of those, and pass it on to the AI engine. The AI engine can even generate a basic complete fully suggested care plan for that patient, and that will be suggested to the doctor. Again, at the end of the day, it's the doctor's responsibility to finalize to sign off on the care plan, or the care plan the doctor can want to use. But I think that should just help you to kind of understand that that's the level. There could be 50 different variables that could have been passed to these open APIs. The results can be received, we can parse it, compile it, and can suggest the information to the doctor. It can help in the identification of rare diseases or submitting all this information. In the case of a rare disease, our system can suggest leveraging the same AI that this patient could have been infected by this one rare disease doctor. So please conduct these 5 additional tests as an example. These are some of the examples that is how we are trying to leverage. We will communicate with the help of the press releases either late in this quarter or early in the third quarter. By that time, we should have a first integrated AI-based, whether it's leveraging the open APIs or the ChatGPT's open APIs, that product, we expect that to release.

Okay. That's helpful. And tied in a little bit to requirements on your hardware and backbones there as far as GPUs, CPUs, stores, some of the requirements on cloud or hardware on your end?

With the advancements in technology, most of these concerns have become obsolete because being in the cloud is so straightforward. If you need to boost processing power, it only takes a mouse click and approval. Since our infrastructure has been efficiently deployed across various cloud environments, we don't anticipate any challenges related to it. Additionally, the cost of increasing small hardware is minimal as we are not looking to purchase an entirely new server from scratch. Therefore, we do not foresee any problems in that area.

Okay. That's helpful. And then lastly for us for, I guess, for Bill or Mahmud, any commentary on the M&A environment, how things have moved in any particular direction or trends over the past, say, 4 or 5 months?

Yes. Good question, Jeff. We continue to see companies that on the surface look like potentially interesting acquisition targets. We also continue to see people have expectations that are probably very good for them but don't make a whole lot of economic sense for us. So we're going to continue to do what we've done in the past, which has kind of applied this rule of thumb that says, 'I'd like, but I'm doing a transaction. I'd like to think that I'm going to get a return on my investment in 3 to 4 years. I'm going to get profits or cash flows equal to what I invested in 3 to 4 years. And if we feel pretty confident, then it looks like it's going to be a good investment for our shareholders.' If the company has a valuation that's 5x revenue, and they've never been profitable, and you don't see any way that it's going to make sense, then we'll pass. And we're continuing to see that. We do think that as the next 12 months unfold, eventually, the economy is going to get into a recession. Eventually, companies are going to start to recognize that they're getting in trouble, and there are going to be some tempting targets. So we're always looking for those.

Your next question comes from Allen Klee at Maxim Group LLC.

When you broke out the pieces of the decline in revenues, one of them was more volume related to COVID-related cases in 1Q '22. Do you have a sense of how much extra do you think that factored into the rest of '22? And have you factored that into your full-year guidance?

Thanks, Allen. So we did some work for a couple of organizations that were doing large-scale COVID testing. And there was a lot of that revenue that actually did happen in the first quarter of '22 in part because some claims sort of got delayed and then finally got approved and therefore, generated a bulk of revenue. So there's a little more that's in the next three quarters. It certainly was much less than we saw in Q1. So I think Q1 of '22 was kind of extraordinary in that regard. I would say that we've probably all seen that very few people are going to labs for COVID tests today. A lot of people are doing COVID at home. So there's not a whole lot of revenue from COVID testing. And it's probably good for us that the COVID is largely at the rearview mirror at this point. But that was certainly a factor in Q1 when you're doing the year-over-year comparison.

And you mentioned that you have, oh, go ahead, sorry.

Sorry, I don't know with your question. Yes, it has been baked in, and we do also see towards the tail end instead of the COVID test revenue. We see some opportunities, though it's not as big as the COVID testing was initially for evolving in those certain labs that have been authorized to send the free test kits to the patients under the government program. Though the public health emergency is ending, most of that is going away, and it's still the number is not, but that's going to help us offset some of that. And all this has already been baked in for the rest of the year.

That's great. You mentioned that you have a new Force client that will be generating revenue in the second half. Can you provide any color on that?

Sure. This deal was signed towards the end of last year. Typically, small Force deals can start within 30 to 60 days. However, since we are working with a large publicly traded national company that requires a couple hundred employees, we need to go through the sharing and agreement of standard operating procedures, extensive training on both sides, and data security checklist verifications. We are currently navigating all of these processes, and everything is progressing smoothly. Nonetheless, the go-live timeframe may extend from 30 to 60 days to between two to three quarters. We expect the largest deal to go live around the close of the second quarter, with revenue anticipated in the third and fourth quarters. The second largest deal has already gone live this month, and we are receiving positive feedback from clients, which means we will see some revenue from that in the second quarter. This is our first major deal for the Force in this sector, and we hope it will lead to more opportunities with other large organizations in the country.

That's great. My last question is on converting bookings from wellness to revenues. You're using a third party, my understanding is to make this happen. Can you explain a little to the degree to what they're doing to ensure adherence and collectability and that they're doing it and not the doctor's office, which I know with some other companies has created a challenge for those two issues?

Sure. Great question. If you think about it, we were a tech-enabled RCM and EHR practice management and in the technology company; that's what our strengths have been for such a long time. The chronic care and remote patient we stepped in, there was one thing we do not want to, day one, start by doing over ourselves as an example, training care managers. So some of those as a partnership with that company, with the back end there helping us to bridge some of those gaps. But because we are the ones who are capable, we have the most capability on the revenue cycle, on the technology platforms, and software. So most of that work is us sort of collaboratively we are conducting. But when it comes to the care manager part, they have been involved, or they have been participation from our third party. But we are looking at it for our clients; for them, it's us. It's our responsibility to work with that third party to deliver the right results. So as I mentioned, just because the three pieces involved: one is us, the second thing is the client, and the third piece is the patient's adaptability. That's why it's taking a little more time to ramp up; we absolutely anticipated the same from day one when we stepped into this. But this means the first go-live. I think by the end of this year, we will have a much better model to forecast when and how the revenue will be recognized. But I think so far, we are making great progress. As I mentioned, over 90% has already been in the production or preproduction stages, or we are conducting eligibility checks, or we are engaging the patients to take their consent, or we already have started to talk to the patient through the help of the care managers, taking approval and review by the physician and have started providing the preventative care and can start submitting the claims.

Your next question comes from Neil Chatterji at B. Riley Financial.

Thanks for the color on the kind of second-half strength versus first-half. Maybe just kind of quarterly cadence on the top line for the rest of '23. I guess a couple of things there. Just how should we think about the potential dollar impact on the two clients rolling off to the second quarter? And then how should we think about just the third quarter versus the fourth quarter, maybe for the CareCloud Force and wellness conversion, with that contribution to be more kind of back-end loaded in the second half or kind of more evenly distributed?

Thanks, Neil. So in terms of the quarterly cadence, the two clients that rolled off last year, for the most part, their use of services dropped by the end of the second quarter. So for example, if you look in 2022, you saw that the third-quarter revenue was about $3.5 million less than the second quarter, and that was almost entirely due to those lines. So what you're going to see when you do the comparison, Q1 of '23 to Q1 of '22, you're looking at a quarter without the clients versus with, so you see a negative. You're going to have the exact same phenomenon in Q2. By the time you get to Q3 and Q4, you'll be comparing against a period when those clients were largely down. I say largely because, as you would expect with a large hospital, it's not like they were doing $12 billion of business one day and 0 the next day. Gradually one group after another moved off. But the bulk of the business was out in the second half of the year. So when we do that comparison in third and fourth quarters, you won't have that phenomenon. When you think about both Wellness and Force, what you're seeing is business signed last year going live, as Hadi mentioned, with these two Force clients, one of them started using billable work in April. Another one is going to be going live by the end of the quarter. So you'll start to see real revenue in Q3 and even more revenue than that in Q4. Similarly, with Wellness, you have a little bit of revenue right now. But overall, the business that we signed up for last year, while we are working with most of those doctor practices, we haven't yet hit the majority of the patients. As this thing rolls out, you'll see it kind of roll exponentially. So I think you're going to see a phenomena that's a little different from what we've seen in the past. In some respects, some of those costs, and clearly, when we're providing more services, we need more people. But for example, the people who are doing the work on these two big Force deals, they're here. I mean, as to doing background checks from the people, they're on the payroll. They're in the cost of goods sold in the first quarter, just not billable. By the time you get to the third and fourth quarters, they will be billable. So a lot of that extra revenue goes straight to the bottom line.

Got it. Great. And then just one follow-up here. Just on gross margins. You might have touched on it a little bit there on the COGS. But I think there was the seasonality impact of the deductibles kind of depressing sales and not as much on the cost side. Just curious on kind of the expectations on gross margins for the balance of '23.

Good question. So I think when you're looking at Q2, Q2 numbers are not going to be so dramatically different than Q1. So I probably think about the gross margin in Q2 being pretty similar. As you get into Q3, you're going to see revenue growing. You're going to see some costs growing, but not as fast. So you're going to see gross margins increasing. And by the time you get to Q4, you're going to see a significant increase in gross margins. I would expect, it's hard to predict this. But I would expect that by the time you get to Q4, you're going to see a higher level of gross margins and probably even a higher percentage of adjusted EBITDA than we've ever shown before because you're going to be seeing this rapid growth in revenue. So don't expect that in Q2. Don't expect to see improvement in Q3. But I would look at Q4 as being the point to look at and say, the business is getting a little closer to a steady state now.

Got it. And just one last quick follow-up. Just on the sales force. I think you had a meaningful increase in '22. Just kind of curious about how to think about that in terms of potentially expanding more at all in '23. And then just remind us on the typical productivity ramp there.

Sure, Neil, thanks for the question. And this is Hadi. Yes, you're right from the overall expense standpoint. We mentioned we anticipate increasing from 7% to 8% in terms of the percentage for sales and marketing expenses from the workforce perspective. I shared this number on my last call when we spoke at the beginning of this year; the number of entire sales and marketing people was somewhere around 55-ish, and today, that number is close to 67% to 68%. And I'm talking about the overall sales and marketing team offshore and onshore together. So yes, we continue to increase as we see that we keep on making progress and we can keep on signing the deals. You can see that in terms of the first quarter booking numbers, it's, again, $8 million; it's almost similar to the fourth quarter last year.

I think it's by the time from when any salesperson joined us. And first of all, we tried to hire someone who already had been coming from at least the healthcare industry with an understanding of what they are selling, plus a lot of experience at least in general sales and marketing. Three months is a good time frame for what we see from the day the person joins to the day when the person should become effective. Between these three months, the trainings are conducted on other product lines, the tools that we are using, at least 30 days; the person gets scheduled by another experienced salesperson. When the engagement is done, one of our experienced salespeople also stays on the call to make sure the right pitch has been done, and the deal gets closed. I think in the fourth month and fifth month, the person should start getting it independently and start selling the deals.

Your next question comes from William Sutherland at the Benchmark Company.

I was thinking maybe to get you to get a little more color on the Middle East initiative in terms of kind of a time frame that you're starting to think about and what the financial implications could be particularly as you ramp it up. And then kind of maybe even touch on the potential that you see.

So the way we are looking at this opportunity, there are three major opportunity areas for us. One is our revenue cycle management capability. The second one is our EHR for ambulatory practices, though that percentage is very small in the UAE, the Middle East market. Most of that comes under the government. The third piece is our Medicare-related professional services business. It could be a Meditech implementation, or it could be a Cerner implementation. So these are the three large areas. I think where we can bring in a lot of value in addition to our market reputation and two decades of experience in the industry on the U.S. side, and then a cost-effective global workforce, primarily from Pakistan. It's about a two-hour flight, roughly a three-hour flight from Pakistan. There are no issues for the visa. The employees can travel there, and we can provide the same solution in a much more cost-effective way. All that can be represented at so many different numbers in terms of the TAM when you go and start doing the search, but there is one consistent thing that over the next six or seven years, this health sector in the Middle East is expected to grow at a CAGR of roughly over 30% or around 30%. I think that opens a lot of doors for us, especially for the early adapters to step in when it's in the early stages of this evolution that's going to come in those countries. As I mentioned, from setting up the entity and all that, we are almost done. There are a few minor things that have been left behind. We will do a groundbreaking. We will be presenting. We will have a booth at that export at that rate show. We'll be speaking. Our leadership for Medicaid will be speaking there. So we'll start engaging, whether it's the government-based authority or government-related people or the other competition in that area. We will keep on sharing the information, but I think this year towards the end of this year, we hope we should be able to start closing some business from that area.

Okay. That sounds like it will probably be starting out with the Med SR kind of implementation.

You are absolutely right, Bill. Those can, because the hospital implementation will ramp up significantly what it is today based on the government initiatives. And those large health system implementations since even before we acquired this company, we had 20 years or 2 decades of experience in this activation, implementation, training, and all of those things, and even providing internal CIOs as an example. Whether we are providing those from our U.S. workforce or from the Pakistan workforce, I think we have a good handle and experience on how to pull these projects off, especially with the American team. The team has done an implementation of 400 FTEs, 500 FTEs, the largest one on the U.S. side. So that combination should absolutely help us do a similar thing in the Middle East in a much more cost-effective way.

Okay. And one more for me. Bill, I wanted to think about the implications, the blended gross margin as you begin to convert these bookings in Force and Wellness, and they become a more meaningful part of the revenue mix. Maybe just characterize the different kind of gross margins that we should be seeing across the business lines?

So I think that one of the things that you need to think about in terms of the gross margin is in the first quarter, in the results that we just published, you've got cost without offsetting revenues. So clearly, some of that is, again, as you're getting started, so that's kind of depressing the gross margin. I think that we find that we can get very good margins in our Force business. That should be as good as our typical margins for the rest of our healthcare-enabled services. I think with wellness day one, you're going to see a little bit lower level of margin in part because we're relying a little more on a third party and in part because we're going to start off overstaffing, putting in more people, making sure we're doing things right. Over time, you'll see the margins in Wellness improve. But I think that I would look at 2024; you'll see margin expansion coming from wellness. So in the second half of '23, as wellness revenue grows, some of that will probably be at a slightly lower level of gross margin, but it will be offset enough by the new clients and everything else that you'll sort of see by the time you get to Q4, a meaningful expansion in our overall gross margin.

Your next question will come from Constantine Davides at EF Hutton.

You guys have obviously done a great job of adding some new services and solutions over the past several quarters. I guess we've all been focused on the upsell opportunity of those services into your legacy base. But what I'm wondering is, you look back four, five, six quarters. Are you starting to see that you're able to swim maybe a bit more upstream in terms of attracting new logos? That is to say, are you seeing sort of more enterprise opportunities than you have in years past?

So let's take an example of this therapy EHR that we launched. If you think about it, therapy today based on the number of providers in the world, let's say, the third-largest specialty. We do not have or until now, we did not have our own EHR designed for therapy practices. Though this market has been dominated by some of these large players who have been in this industry for such a long time, whether it's maybe and a number of others. So today, the way it works is the client ever in this space may have been using one of these other industry EHRs. In some cases, we have interfaces; in other cases, our employees connect to those EHR systems remotely wherever it needs to. But all the rest of the RCM work has been done and all the other pieces by our team members to our platform. So now for us, if you think about it being the third-largest specialty, it makes more sense for us to, first of all, penetrate our existing client base because that's where the easy opportunity exists. But that does not mean that we do not launch it externally. We do launch it externally at the same time, and we do get some of those deals from external. But the easy sell or the opportunity that exists within our company is far better than, or is low-hanging fruit, I would say, instead of going to the external one. Since this is something new, we just started, we still need to spend probably another few quarters before we can go full force externally with large campaigns. Talking about Wellness as an example, in 2022, our primary focus, most of the focus was on our internal client base. This year, we have gone or we have a, you can say, 50% to 50%. We anticipate 50% of the bookings should come from our internal client base, and the other 50% should come from the new logos. This could even become the anchor. This could even become one of the services we are offering, but we will try to sign the full end-to-end deal, including RCM. We have already started to see some results, and we did sign a few clients in the first quarter, the new logos from the Wellness offering. To your point, we already have started to see that, and our campaigns are in progress, and we are making progress there.

There are no other questions. So I will turn the conference back to Kimberly Blanche for any closing remarks.

On behalf of the company, I'd like to thank everyone who joined us on today's call. We appreciate your participation and your interest in us as a company, and we look forward to speaking with you again next quarter. Thank you all, and have a great day.

Thank you.

Ladies and gentlemen, this does conclude your conference call for this morning. Again, thank you all for participating, and we ask that you please disconnect your lines.